Acrivon Therapeutics (ACRV) director receives 9,366 RSUs award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Acrivon Therapeutics director Derek DiRocco received a grant of 9,366 restricted stock units (RSUs) of Common Stock. The award was made as a grant or other acquisition at a price of $0.00 per share, leaving 9,366 shares reported as held after the transaction.
Each RSU represents a contingent right to receive one share of Acrivon Therapeutics, Inc. Common Stock and will vest in full on May 18, 2027, subject to continuous service through that date. Under DiRocco’s arrangement with RA Capital Management, L.P., he holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., must turn over any stock received upon settlement to RA Capital Management, and therefore disclaims beneficial ownership of these RSUs and the underlying common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
DiRocco Derek
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 9,366 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 9,366 shares (Direct, null)
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs and underlying common stock.
Key Figures
RSUs granted: 9,366 units
Grant price: $0.00 per share
Shares following transaction: 9,366 shares
+1 more
4 metrics
RSUs granted
9,366 units
Restricted stock units of Common Stock granted to Derek DiRocco
Grant price
$0.00 per share
Price per share for the RSU grant
Shares following transaction
9,366 shares
Total reported holdings after the RSU grant
Vesting date
May 18, 2027
RSUs vest in full on this date, subject to continuous service
Key Terms
restricted stock units ("RSUs"), beneficial ownership, advisory fees, continuous service
4 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the RSUs and underlying common stock."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
advisory fees financial
"which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser."
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
continuous service financial
"These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service"
FAQ
What insider transaction did Acrivon Therapeutics (ACRV) report for Derek DiRocco?
Acrivon Therapeutics reported that director Derek DiRocco received a grant of 9,366 restricted stock units of Common Stock. The units were awarded at a price of $0.00 per share and are reported as 9,366 shares following the transaction, subject to future vesting conditions.
When do Derek DiRocco’s RSUs in Acrivon Therapeutics (ACRV) vest?
The 9,366 restricted stock units granted to Derek DiRocco vest in full on May 18, 2027. Vesting is contingent on his continuous service through that date, meaning he must remain in an eligible service role until the RSUs vest completely.
What does it mean that Derek DiRocco’s ACRV award consists of RSUs?
The award consists of restricted stock units, each representing a contingent right to receive one share of Acrivon Therapeutics Common Stock. DiRocco does not receive actual shares until vesting and settlement occur, at which point RSUs convert into common shares if vesting conditions are satisfied.
Why does Derek DiRocco disclaim beneficial ownership of his ACRV RSUs?
He disclaims beneficial ownership because he is obligated to turn over any stock received upon RSU settlement to RA Capital Management. The shares benefit RA Capital Healthcare Fund and RA Capital Nexus Fund II, so DiRocco states he does not have beneficial ownership of the RSUs or underlying stock.